Preliminary Results of an Open-Label, Single-Arm, Multi-Center Study on Disitamab Vedotin (DV) Combined with Toripalimab and Radiotherapy As Bladder-Preserving Therapy in HER2 Overexpression Muscle-Invasive Bladder Cancer (MIBC; DECIDING Study-Stage I).